Stocks Health care GRFS

NASDAQ · Health care

Grifols SA (GRFS)

Grifols SA reported revenue of €7.2B in fiscal 2024, up 9.4% from a year earlier. Net income was €156.9M, a net margin of 2.2%. Operating cash flow minus capital spending left €669.6M of free cash flow in fiscal 2024. At December 31, 2024 it held €979.8M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 17, 2026.

Watch GRFS in 60 seconds

What Grifols SA does

Grifols SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GRFS.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in EUR.

Key figures

Full financial statements: income, balance sheet and cash flow

Where GRFS ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out €962K in cash dividends, 1% of its net income.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Grifols SA has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. July 30, 2026
   Foreign issuer update 6-K
2. July 29, 2026
   Foreign issuer update 6-K
3. June 22, 2026
   Foreign issuer update 6-K
4. June 18, 2026
   Foreign issuer update 6-K
5. May 15, 2026
   Foreign issuer update 6-K
6. May 14, 2026
   Passive stake changed SCHEDULE 13G/A
7. May 7, 2026
   Foreign issuer update 6-K
8. April 17, 2026
   Annual report (foreign issuer) 20-F · period to December 31, 2025
9. April 14, 2026
   Foreign issuer update 6-K
10. March 24, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 3, the latest on April 4, 2017. Insider transactions on SEC

Insider trades

What the people running Grifols SA did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns GRFS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

No insider reported holdings on a Form 4 in the last 12 months.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about GRFS

What does Grifols SA do?

Grifols SA is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GRFS.

Is Grifols SA profitable?

Yes. In fiscal 2024 it reported net income of €156.9M on revenue of €7.2B, a net margin of 2.2%.

How much revenue does Grifols SA make?

In fiscal 2024 Grifols SA reported revenue of €7.2B. That is 9.4% more than a year earlier.

When did Grifols SA last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 17, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from July 30, 2026.

Similar companies

Compare GRFS with

Compare GRFS with any company

Follow GRFS

Get an email when Grifols SA files with the SEC: results, executive changes, material agreements and annual reports.

Follow GRFS: get an email when it files

Where the numbers come from

Financial figures are the values Grifols SA tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.